Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Teacher Retirement System of Texas

Teacher Retirement System of Texas raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 19.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,412 shares of the biotechnology company’s stock after purchasing an additional 4,076 shares during the quarter. Teacher Retirement System of Texas’ holdings in Sarepta Therapeutics were worth $3,090,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Manchester Capital Management LLC grew its position in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 156 shares in the last quarter. Sunbelt Securities Inc. increased its stake in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares during the period. Newbridge Financial Services Group Inc. acquired a new stake in Sarepta Therapeutics in the fourth quarter valued at about $36,000. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 194 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on SRPT shares. Piper Sandler reduced their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft reduced their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a report on Wednesday, March 19th. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Finally, HC Wainwright restated a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, March 19th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $167.41.

Insider Activity

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now directly owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Down 3.6 %

SRPT stock opened at $73.61 on Wednesday. Sarepta Therapeutics, Inc. has a one year low of $72.17 and a one year high of $173.25. The stock has a market capitalization of $7.14 billion, a P/E ratio of 58.89 and a beta of 0.79. The company has a 50 day moving average price of $105.44 and a two-hundred day moving average price of $117.08. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.